Table 2.
Avipoxvirus vector-based vaccines licensed for commercial veterinary use
| Recombinant viral vector | Inserts | Targeted Pathogen | Species | Distributor | Country | References |
|---|---|---|---|---|---|---|
| ALVAC | G | Rabies virus | Cats | Merial, Inc. | USA, Canada | [109] |
| ALVAC | HA and F | Canine distemper virus | Dogs, ferrets | Merial, Inc. | USA, Argentina, Brazil, Colombia, Canada, Uruguay | [132] |
| ALVAC | PrM-E | West-Nile virus | Horses | Merial, Inc. | USA, Canada | [133,134] |
| ALVAC | Env, Gag/pol | Feline leukaemia virus | Cats | Merial, Inc. | Europe, USA, Canada | [135-137] |
| FWPV | H5 HA | Avian influenza virus | Chickens | Merial, Inc. | USA, Canada | [110] |
| ALVAC (plus tetanus toxoid and Carbopol adjuvant) | HA | Equine influenza virus | Horses | Merial, Inc. | Europe, USA | [111] |
| FWPV | HN and F | Newcastle disease virus | Chickens | Biomune | USA | [13,138] |
| FWPV- Laryngotracheitis Vaccine | LT+AE | Infectious Laryngotracheitis virus | Chickens | Biomune Co. (Lenexa, KS, USA) | USA | [139] |
| FWPV- Mycoplasma gallisepticum Vaccine | MG+AE | Avian Encephalomyelitis and Mycoplasma gallisepticum | Chickens | Biomune Co. | USA | [140] |
Note: HA from influenza virus H5; HA, hemagglutinin; HN, haemagglutinin-neuraminidase protein; ALVAC, attenuated canarypox virus; FWPV, fowlpox virus; F, fusion protein; G, glycoprotein G; Env, envelope glycoprotein; Gag, group specific antigen; Pro, protease; prM-E, pre-membrane and envelope proteins; MG+AE, Mycoplasma gallisepticum + Avian Encephalomyelitis; LT+AE, Laryngotracheitis virus+Avian Encephalomyelitis.